Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Remdesivir

FDA-approved product (powder, intravenous), marketed as Veklury.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Remdesivir
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Coronavirus infectious disease
  • COVID-19
  • Severe acute respiratory syndrome
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Nucleosides and nucleotides excl. reverse transcriptase inhibitors
FDA pharmacologic class
SARS-CoV-2 Nucleotide Analog RNA Polymerase Inhibitor FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AB16

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA42.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli42.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae31.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis49.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Remdesivir in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Remdesivir with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Risk Stratification of COVID-19 Using Urine Biomarkers

    NCT04681040 · start 2020-09-15

    Registered record
    Registry ID
    NCT04681040
    Conditions
    Covid19; Urine; Biomarker; Acute Respiratory Failure With Hypoxia
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2020-09-15
    Completion
    2024-03-25
    Enrolment
    964

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCovid19; Urine; Biomarker; Acute Respiratory Failure With Hypoxia
    InterventionNot recorded
    PhaseNot recorded
    Registry statusUnknown

  • Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19

    NCT04386447 · start 2020-09-01

    Registered record
    Registry ID
    NCT04386447
    Conditions
    Covid-19; Corona Virus Infection; SARS-CoV 2
    Interventions
    Oxytocin; Standard of Care
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2020-09-01
    Completion
    2020-12-31
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCovid-19; Corona Virus Infection; SARS-CoV 2
    InterventionOxytocin; Standard of Care
    PhasePhase 2
    Registry statusWithdrawn

  • LY3819253 (LY-CoV555) for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

    NCT05780268 · start 2020-08-05

    Registered record
    Registry ID
    NCT05780268
    Conditions
    COVID-19
    Interventions
    LY3819253; Placebo; Remdesivir
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2020-08-05
    Completion
    2021-02-01
    Enrolment
    314

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOVID-19
    InterventionLY3819253; Placebo; Remdesivir
    PhasePhase 3
    Registry statusCompleted

  • ACTIV-3: Therapeutics for Inpatients With COVID-19

    NCT04501978 · start 2020-08-04

    Registered record
    Registry ID
    NCT04501978
    Conditions
    Covid19
    Interventions
    LY3819253; Placebo; Remdesivir; VIR-7831; BRII-196/BRII-198; AZD7442; MP0420; PF-07304814
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2020-08-04
    Completion
    2023-07-14
    Enrolment
    2,753

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCovid19
    InterventionLY3819253; Placebo; Remdesivir; VIR-7831 +4 more
    PhasePhase 3
    Registry statusCompleted

  • I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients

    NCT04488081 · start 2020-07-31

    Registered record
    Registry ID
    NCT04488081
    Conditions
    COVID-19
    Interventions
    Remdesivir; Imatinib Mesylate; Dexamethasone; Cenicriviroc; Icatibant; Apremilast; dornase alfa; Celecoxib; Famotidine; IC14; Aviptadil; narsoplimab; Cyproheptadine; Cyclosporine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2020-07-31
    Completion
    2030-07-31
    Enrolment
    1,500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOVID-19
    InterventionRemdesivir; Imatinib Mesylate; Dexamethasone; Cenicriviroc +10 more
    PhasePhase 2
    Registry statusActive not recruiting

  • Australasian COVID-19 Trial (ASCOT) ADAptive Platform Trial

    NCT04483960 · start 2020-07-28

    Registered record
    Registry ID
    NCT04483960
    Conditions
    SARS-CoV-2 Infection (COVID-19)
    Interventions
    (Arm Closed) Nafamostat Mesilate; (Arm Closed) Enoxaparin; (Arm Closed) Dalteparin; (Arm Closed) Tinzaparin; (Arm Never Opened) Hyperimmune globulin; Nirmatrelvir-Ritonavir; Remdesivir
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2020-07-28
    Completion
    2025-12-31
    Enrolment
    2,200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSARS-CoV-2 Infection (COVID-19)
    Intervention(Arm Closed) Nafamostat Mesilate; (Arm Closed) Enoxaparin; (Arm Closed) Dalteparin; (Arm Closed) Tinzaparin +3 more
    PhasePhase 3
    Registry statusUnknown

  • Remdesivir Efficacy In Management Of COVID-19 Patients

    NCT04853901 · start 2020-07-27

    Registered record
    Registry ID
    NCT04853901
    Conditions
    Covid19
    Interventions
    Remdesivir; Standard of care_1; Standard of care_2
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2020-07-27
    Completion
    2021-03-01
    Enrolment
    77

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCovid19
    InterventionRemdesivir; Standard of care_1; Standard of care_2
    PhasePhase 3
    Registry statusCompleted

  • A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia

    NCT04409262 · start 2020-06-16

    Registered record
    Registry ID
    NCT04409262
    Conditions
    COVID-19 Pneumonia
    Interventions
    Remdesivir; Tocilizumab; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2020-06-16
    Completion
    2021-03-08
    Enrolment
    649

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOVID-19 Pneumonia
    InterventionRemdesivir; Tocilizumab; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Austrian CoronaVirus Adaptive Clinical Trial (COVID-19)

    NCT04351724 · start 2020-04-16

    Registered record
    Registry ID
    NCT04351724
    Conditions
    COVID-19
    Interventions
    Chloroquine or Hydroxychloroquine; Lopinavir/Ritonavir; Best standard of care; Rivaroxaban; Thromboprophylaxis; Candesartan; non-RAS blocking antihypertensives; Remdesivir; Asunercept 400mg; Asunercept 100mg; Asunercept 25mg; Pentaglobin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2020-04-16
    Completion
    2022-03-31
    Enrolment
    500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOVID-19
    InterventionChloroquine or Hydroxychloroquine; Lopinavir/Ritonavir; Best standard of care; Rivaroxaban +8 more
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • A Systems Approach to Predict the Outcome of SARS-CoV-2 in the Population of a City; COVID-19

    NCT04351503 · start 2020-04-09

    Registered record
    Registry ID
    NCT04351503
    Conditions
    SARS Coronavirus (SARS-CoV-2) Infection
    Interventions
    Study A; Study B; Study C; Study D
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-04-09
    Completion
    2022-07-31
    Enrolment
    126,586

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSARS Coronavirus (SARS-CoV-2) Infection
    InterventionStudy A; Study B; Study C; Study D
    PhaseNot recorded
    Registry statusCompleted

  • Trial of Treatments for COVID-19 in Hospitalized Adults

    NCT04315948 · start 2020-03-22

    Registered record
    Registry ID
    NCT04315948
    Conditions
    Corona Virus Infection
    Interventions
    Remdesivir; Lopinavir/ritonavir; Interferon Beta-1A; Hydroxychloroquine; Standard of care; AZD7442; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2020-03-22
    Completion
    2023-09-25
    Enrolment
    1,552

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCorona Virus Infection
    InterventionRemdesivir; Lopinavir/ritonavir; Interferon Beta-1A; Hydroxychloroquine +3 more
    PhasePhase 3
    Registry statusCompleted

  • Adverse Events Related to Treatments Used Against Coronavirus Disease 2019

    NCT04314817 · start 2020-03-17

    Registered record
    Registry ID
    NCT04314817
    Conditions
    Coronavirus; Iatrogenic Disease; Acute Kidney Injury; ARDS, Human
    Interventions
    Any drug used to treat Covid-19
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-03-17
    Completion
    2023-01-01
    Enrolment
    1,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronavirus; Iatrogenic Disease; Acute Kidney Injury; ARDS, Human
    InterventionAny drug used to treat Covid-19
    PhaseNot recorded
    Registry statusCompleted

  • Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

    NCT04278404 · start 2020-03-05

    Registered record
    Registry ID
    NCT04278404
    Conditions
    Coronavirus Infection (COVID-19); Pulmonary Arterial Hypertension; Urinary Tract Infections in Children; Hypertension; Pain; Hyperphosphatemia; Primary Hyperaldosteronism; Edema; Hypokalemia; Heart Failure; Hemophilia; Menorrhagia; Insomnia; Pneumonia; Skin Infection; Arrythmia; Asthma in Children; Bronchopulmonary Dysplasia; Adrenal Insufficiency; Fibrinolysis; Hemorrhage; Attention Deficit Hyperactivity Disorder; Multisystem Inflammatory Syndrome in Children (MIS-C); Kawasaki Disease; Coagulation Disorder; Down Syndrome
    Interventions
    The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2020-03-05
    Completion
    2026-12
    Enrolment
    5,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronavirus Infection (COVID-19); Pulmonary Arterial Hypertension; Urinary Tract Infections in Children; Hypertension +22 more
    InterventionThe POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
    PhaseNot recorded
    Registry statusRecruiting

  • Adaptive COVID-19 Treatment Trial (ACTT)

    NCT04280705 · start 2020-02-21

    Registered record
    Registry ID
    NCT04280705
    Conditions
    COVID-19
    Interventions
    Placebo; Remdesivir
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2020-02-21
    Completion
    2020-05-21
    Enrolment
    1,062

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOVID-19
    InterventionPlacebo; Remdesivir
    PhasePhase 3
    Registry statusCompleted

  • A Trial of Remdesivir in Adults With Mild and Moderate COVID-19

    NCT04252664 · start 2020-02-12

    Registered record
    Registry ID
    NCT04252664
    Conditions
    COVID-19; SARS-CoV-2
    Interventions
    Remdesivir; Remdesivir placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Suspended
    Start
    2020-02-12
    Completion
    2020-04-27
    Enrolment
    308

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOVID-19; SARS-CoV-2
    InterventionRemdesivir; Remdesivir placebo
    PhasePhase 3
    Registry statusSuspended